Immunic, Inc. (IMUX) — insider trading
Health Care · NASDAQ
Immunic, Inc. (IMUX) has 20 reported SEC Form 4 insider transactions in our data (latest 2026-09-16).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-16 | Nagel Robert Thorvald | Director | Grant / award / vesting (derivative) | 25,370 | — | $0 | Form 4 |
| 2026-09-16 | BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND L P; BVF I GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF GP HOLDINGS LLC; BVF INC/IL; LAMPERT MARK N | Director, Other | Grant / award / vesting (derivative) | 25,370 | — | $0 | Form 4 |
| 2026-08-06 | Ridloff Elena | Director | Grant / award / vesting (derivative) | 50,740 | — | $0 | Form 4 |
| 2026-07-05 | Congleton Jon | Director | Grant / award / vesting (derivative) | 25,370 | — | $0 | Form 4 |
| 2026-07-05 | Neermann Joerg | Director | Grant / award / vesting (derivative) | 25,370 | — | $0 | Form 4 |
| 2026-07-05 | PHILLIPS BARCLAY A | Director | Grant / award / vesting (derivative) | 25,370 | — | $0 | Form 4 |
| 2026-07-05 | Rudick Richard Alan | Director | Grant / award / vesting (derivative) | 25,370 | — | $0 | Form 4 |
| 2026-07-05 | Skerjanec Simona | Director | Grant / award / vesting (derivative) | 25,370 | — | $0 | Form 4 |
| 2026-06-29 | BONNEY MICHAEL W | Director | Grant / award / vesting (derivative) | 100,000 | — | $0 | Form 4 |
| 2026-06-29 | Vitt Daniel | Director | Grant / award / vesting (derivative) | 445,000 | — | $0 | Form 4 |
| 2026-06-29 | Whaley Glenn | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 120,000 | — | $0 | Form 4 |
| 2026-06-29 | Tardio Jason | Officer (President and COO) | Grant / award / vesting (derivative) | 253,000 | — | $0 | Form 4 |
| 2026-06-29 | PHILLIPS BARCLAY A | Director | Grant / award / vesting (derivative) | 25,370 | — | $0 | Form 4 |
| 2026-06-29 | Neermann Joerg | Director | Grant / award / vesting (derivative) | 25,370 | — | $0 | Form 4 |
| 2026-06-29 | HOWSON TAMAR D | Director | Grant / award / vesting (derivative) | 25,370 | — | $0 | Form 4 |
| 2026-06-29 | Rudick Richard Alan | Director | Grant / award / vesting (derivative) | 25,370 | — | $0 | Form 4 |
| 2026-06-29 | Skerjanec Simona | Director | Grant / award / vesting (derivative) | 25,370 | — | $0 | Form 4 |
| 2026-06-29 | Congleton Jon | Director | Grant / award / vesting (derivative) | 50,740 | — | $0 | Form 4 |
| 2026-05-22 | Lundgren Erik | Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 1,000,000 | — | $0 | Form 4 |
| 2026-04-24 | Panzara Michael A. | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 300,000 | — | $0 | Form 4 |
Ask the chat about IMUX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Immunic, Inc. (IMUX).
Last updated 2026-09-16 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.